This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Visalli, M. A. Articles by Appelbaum, P. C. Search for Related Content PubMed PubMed Citation Articles by Visalli, M. A. Articles by Appelbaum, P. C.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., Dec 1997, 2786-2789, Vol 41, No. 12
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams

MA Visalli, MR Jacobs and PC Appelbaum
Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA.

Activities of BAY 12-8039 against 205 pneumococci were tested by agar dilution. MICs (in micrograms per milliliter) at which 50 and 90% of the isolates are inhibited (MIC50s and MIC90s, respectively) were 0.125 and 0.25 (BAY 12-8039), 2.0 and 4.0 (ciprofloxacin and ofloxacin), and 0.25 and 0.5 (sparfloxacin). Beta-lactam MIC50s and MIC90s for penicillin-susceptible, -intermediate, and -resistant strains, in that order, were 0.016 and 0.03, 0.25 and 2.0, and 2.0 and 4.0 (amoxicillin); 0.03 and 0.06, 0.25 and 4.0, and 4.0 and 8.0 (ampicillin); 0.03 and 0.06, 0.5 and 4.0, and 4.0 and 8.0 (cefuroxime); and 0.03 and 0.125, 0.25 and 2.0, and 4.0 and 8.0 (cefpodoxime). At two times their MICs after 24 h, BAY 12-8039, ciprofloxacin, ampicillin, and cefuroxime were uniformly bactericidal (99.9% killing) against 12 strains; other compounds were bactericidal at four times their MICs.

This article has been cited by other articles:

• Clark, C., Smith, K., Ednie, L., Bogdanovich, T., Dewasse, B., McGhee, P., Appelbaum, P. C. (2008). In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci. Antimicrob. Agents Chemother. 52: 77-84 [Abstract] [Full Text]  
• Kosowska-Shick, K., Credito, K., Pankuch, G. A., Lin, G., Bozdogan, B., McGhee, P., Dewasse, B., Choi, D.-R., Ryu, J. M., Appelbaum, P. C. (2006). Antipneumococcal Activity of DW-224a, a New Quinolone, Compared to Those of Eight Other Agents.. Antimicrob. Agents Chemother. 50: 2064-2071 [Abstract] [Full Text]  
• Ednie, L. M., Pankuch, G., Appelbaum, P. C. (2004). Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents. Antimicrob. Agents Chemother. 48: 4027-4032 [Abstract] [Full Text]  
• Browne, F. A., Bozdogan, B., Clark, C., Kelly, L. M., Ednie, L., Kosowska, K., Dewasse, B., Jacobs, M. R., Appelbaum, P. C. (2003). Antipneumococcal Activity of DK-507k, a New Quinolone, Compared with the Activities of 10 Other Agents. Antimicrob. Agents Chemother. 47: 3815-3824 [Abstract] [Full Text]  
• Hoellman, D. B., Lin, G., Ednie, L. M., Rattan, A., Jacobs, M. R., Appelbaum, P. C. (2003). Antipneumococcal and Antistaphylococcal Activities of Ranbezolid (RBX 7644), a New Oxazolidinone, Compared to Those of Other Agents. Antimicrob. Agents Chemother. 47: 1148-1150 [Abstract] [Full Text]  
• Sahm, D. F., Peterson, D. E., Critchley, I. A., Thornsberry, C. (2000). Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States. Antimicrob. Agents Chemother. 44: 2521-2524 [Abstract] [Full Text]  
• Pong, A., Thomson, K. S., Moland, E. S., Chartrand, S. A., Sanders, C. C. (1999). Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J Antimicrob Chemother 44: 621-627 [Abstract] [Full Text]  
• Wilson, R., Kubin, R., Ballin, I., Deppermann, K.-M., Bassaris, H. P., Leophonte, P., Schreurs, A. J. M., Torres, A., Sommerauer, B. (1999). Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 44: 501-513 [Abstract] [Full Text]  
• Müller, M., Staß, H., Brunner, M., Möller, J. G., Lackner, E., Eichler, H. G. (1999). Penetration of Moxifloxacin into Peripheral Compartments in Humans. Antimicrob. Agents Chemother. 43: 2345-2349 [Abstract] [Full Text]  
• Hoellman, D. B., Lin, G., Jacobs, M. R., Appelbaum, P. C. (1999). Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J Antimicrob Chemother 43: 645-649 [Abstract] [Full Text]  
• Hsueh, P.-R., Teng, L.-J., Lee, L.-N., Yang, P.-C., Ho, S.-W., Luh, K.-T. (1999). Extremely High Incidence of Macrolide and Trimethoprim-Sulfamethoxazole Resistance among Clinical Isolates of Streptococcus pneumoniae in Taiwan. J. Clin. Microbiol. 37: 897-901 [Abstract] [Full Text]